EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia

Wen-Yue Liu, Li-You Lian, Huai Zhang, Sui-Dan Chen, Xin-Zhe Jin, Ni Zhang, Chen-Hui Ye, Wen-Ying Chen, George Goh Boon Bee, Fu-Di Wang, Luca Miele, Elena Corradini und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad749 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Wen-Yue Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Hauptthemen laut MEDLINE: Ferritins, Hyperferritinemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

There is limited data on the clinical significance of metabolic hyperferritinemia (MHF) based on the most recent consensus.

Objective

We aimed to validate the clinical outcomes of MHF in the general population and patients with biopsy-proven metabolic dysfunction–associated fatty liver disease (MAFLD).

Methods

The NHANES database and PERSONS cohort were included. MHF was defined as elevated serum ferritin with metabolic dysfunction (MD) and stratified into different grades according to ferritin (grade 1: 200 [females]/300 [males]—550 ng/mL; grade 2: 550-1000 ng/mL; grade 3: >1000 ng/mL). The clinical outcomes, including all-cause death, comorbidities, and liver histology, were compared between non-MHF and MHF in adjusted models.

Results

In NHANES, compared with non-MHF with MD, MHF was related to higher risks of advanced fibrosis (P = .036), elevated albumin–creatinine ratio (UACR, P = .001), and sarcopenia (P = .013). Although the association between all grades of MHF and mortality was insignificant (P = .122), grades 2/3 was associated with increased mortality (P = .029). When comparing with non-MHF without MD, the harmful effects of MHF were more significant in mortality (P < .001), elevated UACR (P < .001), cardiovascular disease (P = .028), and sarcopenia (P < .001). In the PERSONS cohort, MHF was associated with more advanced grades of steatosis (P < .001), lobular inflammation (P < .001), advanced fibrosis (P = .017), and more severe hepatocellular iron deposition (P < .001).

Conclusion

Both in the general population and in at-risk individuals with MAFLD, MHF was related with poorer clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerritinsHyperferritinemiaAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesConsensusNutrition SurveysPrognosisConsensus Statements as Topic

Stichwörter der Autor:innen

iron overloadmetabolic dysfunction–associated fatty liver diseasemetabolic hyperferritinemiametabolic syndrome

Substanzen

Ferritins

Autor:innen und Institutionen

  • Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
  • Wenzhou Key Laboratory of Diabetes Research, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
  • MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
  • Institute of Hepatology, Wenzhou Medical University, Wenzhou 325000, China.
  • Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou 325000, China.
  • Biostatistics and Medical Quality Management Office, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

ORCID-Profile: Luca Valenti, Ming-Hua Zheng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, W. Y., Lian, L. Y., Zhang, H., Chen, S. D., Jin, X. Z., Zhang, N., Ye, C. H., Chen, W. Y., Bee, G. G. B., Wang, F. D., Miele, L., Corradini, E., Valenti, L., & Zheng, M. H. (2024). A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad749

Vancouver

Liu WY, Lian LY, Zhang H, Chen SD, Jin XZ, Zhang N, et al. A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad749

BibTeX
@article{Liu2024,
  author = {Liu, Wen-Yue and Lian, Li-You and Zhang, Huai and Chen, Sui-Dan and Jin, Xin-Zhe and Zhang, Ni and Ye, Chen-Hui and Chen, Wen-Ying and Bee, George Goh Boon and Wang, Fu-Di and Miele, Luca and Corradini, Elena and Valenti, Luca and Zheng, Ming-Hua},
  title = {A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad749}
}
Kostenlos starten →